The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Immunovia based on the positive results of a recent onsite inspection as part of the CAP’s Accreditation Programs.
The College of American Pathologists congratulated Thomas C. King, MD, PhD, Medical Director of Immunovia for the excellence of the services being provided and advised him of the accreditation.
“This is an exciting day for Immunovia, since CAP accreditation not only signifies the highest quality standards of our laboratory, it also allows us to seek licensure in the five remaining U.S. states, allowing us to roll out the IMMray PanCan-d test to individuals in all 50 states, including California and New York, in the near future, further advancing our mission to make early detection of pancreatic cancer broadly available,” says Philipp Mathieu, Immunovia’s Acting CEO.
Immunovia is now one of the more than 8,000 College of American Pathologists (CAP) certified facilities worldwide.
“This is a huge milestone for the company, as it further solidifies the quality of our laboratory and the services we provide to physicians and their patients at high risk for developing pancreatic cancer with the IMMray PanCan-d test” says King.
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program.
During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
For more information about the accreditation and the College of American Pathologists (CAP), visit www.immunovia.com.